CureVac COVID-19 shows 48% efficacy in clinical trials

German vaccine developer CureVac said Wednesday its COVID-19 vaccine showed 48% efficacy against the virus, including the 15 known variants, in clinical trials.

from Latest News - UPI.com https://ift.tt/3dyOVT4
via IFTTT